Replies to post #24645 on Mymetics Corp (MYMX)

[Work Harder]

Compliments of Maria Elena Bottazzi

https://twitter.com/mebottazzi/status/1387367339696476160/photo/1

Book to attend

https://secure.terrapinn.com/V5/step2.aspx?Q=1923645KDTX&TMID=2006728

[Work Harder]

1.3 milly bid doesn't understand these

are knock offs also

https://www.farfetch.com/shopping/men/bottega-veneta-bermuda-denim-shorts-item-16632732.aspx?storeid=9681

LMAO

[Work Harder]

The research was funded by the Wellcome Trust and the TRANSVAC2 project supported by the European Union’s Horizon 2020 Research and Innovation programme under grant agreement No 730964.

Trial shows York leishmaniasis vaccine safe and induces immune responses in patients

https://4state.news/trial-shows-york-leishmaniasis-vaccine-safe-and-induces-immune-responses-in-patients/

The design of the vaccine is very similar to the Oxford / Astra Zeneca vaccine being used to prevent COVID-19.

Wellcome Trust Translation Award that funded the development of the vaccine.

[Work Harder]

Naarden, The Netherlands and Munich, Germany – 20 April 2021 – Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion Growth I") at the hard cap amount of EUR 360 million (USD 428 million). Forbion Growth I is focused on investing in late-stage European life sciences companies.

Pantheon, Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), the Belgian Growth Fund

https://seekingalpha.com/news/3677515-horizon-therapeutics-to-resupply-tepezza-for-thyroid-eye-disease-in-april

Mamta Mayani

https://seekingalpha.com/news/3677515-horizon-therapeutics-to-resupply-tepezza-for-thyroid-eye-disease-in-april

DVAX Dynavax

https://www.tipranks.com/bloggers/mamta-mayani

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163567063

The lobbying disclosures show that Jeff Ricchetti lobbied the EOP for health-care giants GlaxoSmithKline, Horizon Therapeutics and Vaxart Inc.

Horizon Therapeutics paid Ricchetti $80,000 in the first quarter. He went on to lobby the EOP, Congress and the Department of Health and Human Services on their behalf, including on “issues related to drug pricing and Medicare and Medicaid reimbursement,” the quarterly document says.

A spokesman for Horizon declined to comment for this story.

“The urgent effort to develop a COVID-19 vaccine has focused on injectables and many policymakers don’t know that the Holy Grail is an oral tablet — an oral tablet is easier to distribute, administer, and is stable at room temperature, unlike injectables,” a company spokesman told CNBC. “It also overcomes needle-phobia that many Americans suffer from. We have asked Mr. Ricchetti to help us educate policy makers about the oral tablet option.”

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163557974

[Work Harder]

Lukas Fierz

- The company Vaxart (NASDAQ: VXRT) from San Francisco has been developing oral vaccinations against the diarrhea-causing norovirus and against the uterine cancer-causing papillomavirus for a long time.

Together with Janssen (subsidiary of Johnson & Johnson) she is developing an oral flu vaccination, which in a phase II study gave better results than an established injection vaccination - if confirmed by a phase III study, that would be an absolute sensation.

Vaxart's Covid vaccine gave good protection in animal studies, and a Phase I human trial produced cellular immunity and local Ig-A antibodies, but no IgG antibodies in serum, causing the share price to fall.

This seems unjustified because one in sixteen Covid healed people also has no serum antibodies , and because animal experiments have shown that cellular immunity protects against low levels of antibodies .

And if that vaccination prevented the virus from reaching the bloodstream, the lack of serum antibodies wouldn't be a disadvantage. Only clinical trials can clarify this.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163254853

Thanks to the poster

Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine
July 9, 2019 at 8:00 AM EDT

https://investors.vaxart.com/news-releases/news-release-details/vaxart-enters-research-collaboration-janssen-evaluate-oral

[Work Harder]

Any other reasonable CEO

would have released news today

Vaxart (VXRT) – Vaxart surged 18.6% in premarket trading after it reported positive results in a phase 1 trial of its oral Covid-19 vaccine. Vaxart said the vaccine could be just as effective as the injected vaccines developed by Pfizer and Moderna (MRNA).

[Work Harder]

Why can't Ronald sell some shares

to any of the fund mangers he is trying to ?

Totally impressed w/ Peter Hotez, Maria Bottazzi & Ronald Kempers leadership here

but even more impressed w/ the expert insider management

So I'll just increase the bids

[Work Harder]

More than a few are obviously interested

So why can't he sell them some shares

It isn't enough for them

They don't want to be a part of an equity stake w/ Big Pharma

?

and Director of the Start-up and Spin-off Program from the Swiss Federal Institute of Technology in Lausanne (EPFL). During his tenure, more than 35 spin-offs were launched. In parallel, he served as expert for new ventures creation at the Swiss Federal Commission for Technology and Innovation (CTI) in Bern.

I mean wth

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163563258

Innosuisse replaces CTI: Funding opportunities for Swiss researchers, SMEs and industry

[Work Harder]

Nih Hiv updated today

https://reporter.nih.gov/search/dECpjLDvPk6PQQQ4WMiExA/projects?fy=2021

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163694592